

To Financial Editors:
【For Immediate Release】



TUL Obtained Approval for All Recombinant Human Insulin Products - A New Era Begins

【4 January 2011 - Hong Kong】 - The United Laboratories International Holdings Limited (“TUL” or the “Group”; Stock code: 3933), one of the leading pharmaceutical companies in the PRC, is pleased to announce that the Group has obtained official production approval for three recombinant human insulin products. Production is expected to commence in the near future. These new products will create new impetus for the growth of earnings capabilities going forward.

The newly approved three recombinant human insulin products are Rapid-Acting R(S20100013), Long-Acting 30R(S20100014) and Long-Acting 50R(S20100015). While taking account of the previously approved Intermediate-Acting Recombinant Human Insulin Injection (NS20090030) and Recombinant Human Insulin Bulk Medicine (S20090031), the Group has obtained the approval for all recombinant human insulin products. As a result, the Group’s growth capabilities in terms of market share will largely increase. The Group will organize state and provincial level press conferences with insulin experts to promote the products. Taking the cost advantage, the prices of the products will be 10-15% lower than products of the same category. This would efficiently and effectively help capture market share.

TUL spent 8 years on research and development of the recombinant human insulin products. Afterwards, the Group invited the assessment organizations recognized by the Government to carry out clinical treatment tests and assessment exercises. Results show that the equivalent treatment effectiveness of the new product is equivalent to that of the imported insulin series. The products are mainly used for clinical treatment of type 1 and type 2 diabetes. Such patients usually need lifelong medication. Currently, China's diabetes patients are more than 100 million. The demand for recombinant human insulin products in China is about 6 billion RMB per year. The market expects the demand continues to grow by 20% to 30% each year in the coming future.

Mr. Choy Kam Lok, Chairman of TUL said, “The Group is dedicated to capture the fast-growing Chinese insulin market. We will continue the capital investment of 400 to 500 million RMB in manufacturing the products and developing the market. In the past one year, the feedback on our first recombinant human insulin product was positive. Many hospitals, distributors and patients are waiting for our three new products. With the well-established sales force, network and strategies, the Group foresees a new era driven by the insulin products. We are now conducting research on insulin analogues such as insulin glargine and insulin aspart. We hope that we can launch these two products to market next year. On the other hand, our Inner Mongolia plant has successfully developed technology for Enzymatic Production of Amoxicillin after research in the past few years. This is a world-class technology for effectively producing Amoxicillin medicine with no impurity and minimal

water pollution. Approval is expected to be granted shortly. We believe that the recombinant human insulin products and amoxicillin products will bring considerable earnings for the Group and thus the shareholders.”

- End -

About The United Laboratories International Holdings Limited

Listed on the Stock Exchange of Hong Kong in June 2007, TUL is one of the leading pharmaceutical companies in China, principally engaged in the manufacturing and selling of medicines, and the bulk and intermediate products used to produce finished goods. As of 30 June 2010, the Group has a total of 176 products qualified to produce in the PRC and/Hong Kong based on the Drug Registration Approvals in the PRC and Certificates of Drug or Product Registration in Hong Kong. 76 were in production, and 34 were listed in Insurance Catalogue. 12 finished products are in the list of National Basic Drugs Catalogue. TUL is a constituent of the Hang Seng Composite Index Series. For more information about TUL, please visit the company's website at www.tul.com.hk.

Issued by Creativeline Communications for and on behalf of The United Laboratories International Holdings Limited. For further information, please contact:

Creativeline Communications

Mr. Wayne Chau / Ms. Sylvia Lau

Tel: (852) 2730 6212 / 6390 9406

Fax: (852) 2736 0745

Email: wayne@creativeline.com.hk / sylvia@creativeline.com.hk